PRTG Portage Biotech Inc: רווח למניה ב-12 החודשים האחרונים

Portage Biotech Inc. (PRTG) ensures operational continuity through the distribution of its production sites. The company relies on external contractors for drug development and testing. A broad pipeline of researched molecules reduces overall risks. On GURU.Markets, the annual EPS growth based on financial statements (TTM) demonstrates profit dynamics, where -545.70 represents the latest level value.

EPS TTM growth measures the trailing twelve-month net income per share, reflecting the actual quality of generated revenue. By analyzing the current annual EPS TTM growth rate, an investor can gauge the efficiency of intellectual property monetization. For Portage Biotech Inc. (PRTG), this metric correlates with immuno-oncology screening rates and adherence to contract manufacturing schedules. A stable trajectory confirms the business model's resilience to external shocks, while a positive trend signals a transition from cost-intensive research to asset capitalization.